CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Files Provisional Patent Covering Proprietary Biosynthesis Program
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its filing of a provisional patent application pertaining to the company’s biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature. Per the news release, this patent application, once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions around the world, will offer significant commercial protections for InMed’s promising E. coli-based expression system, which enables the manufacture of any of the 90+ cannabinoid compounds found in the cannabis plant. “This novel approach to the biosynthesis of…